DIANTHUS THERAPEUTICS INC.

NASDAQ: DNTH (Dianthus Therapeutics, Inc.)

最近更新时间: 昨天, 9:24PM

43.97

1.69 (4.00%)

前收盘价格 42.28
收盘价格 42.24
成交量 751,504
平均成交量 (3个月) 828,624
市值 1,885,258,496
价格/销量 (P/S) 517.39
股市价格/股市净资产 (P/B) 3.45
52周波幅
13.37 (-69%) — 44.95 (2%)
利润日期 5 Nov 2025
营业利益率 (TTM) -2,852.71%
稀释每股收益 (EPS TTM) -2.83
季度收入增长率 (YOY) 33.10%
总债务/股东权益 (D/E MRQ) 0.43%
流动比率 (MRQ) 15.98
营业现金流 (OCF TTM) -90.87 M
杠杆自由现金流 (LFCF TTM) -52.44 M
资产报酬率 (ROA TTM) -20.04%
股东权益报酬率 (ROE TTM) -28.73%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Dianthus Therapeutics, Inc. 看跌 看跌

AIStockmoo 评分

0.0
分析师共识 1.0
内部交易活动 NA
价格波动 -5.0
技术平均移动指标 0.0
技术振荡指标 4.0
平均 0.00

相关股票

股票 市值 DY P/E(TTM) P/B
DNTH 2 B - - 3.45
BNTX 23 B - - 1.16
ASND 13 B - - -
IMCR 2 B - - 5.03
JBIO 535 M - - -
NBP 444 M - - 2.25

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

部门 Healthcare
行业 Biotechnology
内部持股比例 7.87%
机构持股比例 119.90%

所有权

姓名 日期 持有股份
Fairmount Funds Management Llc 30 Sep 2025 3,307,191
Octagon Capital Advisors Lp 30 Sep 2025 2,416,667
Vestal Point Capital, Lp 30 Sep 2025 1,180,000
Vr Adviser, Llc 30 Sep 2025 960,803
52周波幅
13.37 (-69%) — 44.95 (2%)
目标价格波幅
46.00 (4%) — 100.00 (127%)
100.00 (Clear Street, 127.43%) 购买
100.00 (Guggenheim, 127.43%) 购买
64.00 (45.55%)
46.00 (Wedbush, 4.62%) 购买
平均值 68.00 (54.65%)
总计 8 购买
平均价格@调整类型 36.42
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 10 Nov 2025 47.00 (6.89%) 购买 36.61
08 Sep 2025 40.00 (-9.03%) 购买 31.80
Wedbush 06 Nov 2025 46.00 (4.62%) 购买 36.43
12 Sep 2025 44.00 (0.07%) 购买 37.16
Truist Securities 14 Oct 2025 56.00 (27.36%) 购买 35.55
Clear Street 17 Sep 2025 100.00 (127.43%) 购买 38.88
Stifel 12 Sep 2025 65.00 (47.83%) 购买 37.16
Baird 09 Sep 2025 67.00 (52.38%) 购买 35.57
Guggenheim 09 Sep 2025 100.00 (127.43%) 购买 35.57
Raymond James 09 Sep 2025 63.00 (43.28%) 购买 35.57

该时间范围内无数据。

日期 类型 细节
24 Nov 2025 公告 Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
05 Nov 2025 公告 Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
04 Nov 2025 公告 Dianthus Therapeutics to Participate in Four Investor Conferences During November
29 Oct 2025 公告 Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
16 Oct 2025 公告 Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
02 Oct 2025 公告 Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
11 Sep 2025 公告 Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
09 Sep 2025 公告 Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
08 Sep 2025 公告 Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
08 Sep 2025 公告 Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
07 Sep 2025 公告 Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票